SG11202006614VA - Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them - Google Patents

Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them

Info

Publication number
SG11202006614VA
SG11202006614VA SG11202006614VA SG11202006614VA SG11202006614VA SG 11202006614V A SG11202006614V A SG 11202006614VA SG 11202006614V A SG11202006614V A SG 11202006614VA SG 11202006614V A SG11202006614V A SG 11202006614VA SG 11202006614V A SG11202006614V A SG 11202006614VA
Authority
SG
Singapore
Prior art keywords
macrocycles
modulators
treatment
making
pharmaceutical compositions
Prior art date
Application number
SG11202006614VA
Other languages
English (en)
Inventor
Jeremy J Clemens
Alexander Russell Abela
Corey Don Anderson
Brett B Busch
Weichao George Chen
Thomas Cleveland
Timothy Richard Coon
Bryan Frieman
Senait G Ghirmai
Peter Grootenhuis
Anton V Gulevich
Ruah Sara Sabina Hadida
Clara Kuang-Ju Hsia
Ping Kang
Haripada Khatuya
Jason Mccartney
Mark Thomas Miller
Prasuna Paraselli
Fabrice Pierre
Sara E Swift
Andreas Termin
Johnny Uy
Carl V Vogel
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SG11202006614VA publication Critical patent/SG11202006614VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202006614VA 2018-02-15 2019-02-14 Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them SG11202006614VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862631453P 2018-02-15 2018-02-15
PCT/US2019/018042 WO2019161078A1 (fr) 2018-02-15 2019-02-14 Macrocycles utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de fibrose kystique, compositions pharmaceutiques de ceux-ci, leur utilisation dans le traitement de la fibrose kystique et procédé de fabrication associé

Publications (1)

Publication Number Publication Date
SG11202006614VA true SG11202006614VA (en) 2020-08-28

Family

ID=65529899

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006614VA SG11202006614VA (en) 2018-02-15 2019-02-14 Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them

Country Status (37)

Country Link
US (2) US11066417B2 (fr)
EP (2) EP4198037A1 (fr)
JP (3) JP7214743B2 (fr)
KR (1) KR102482271B1 (fr)
CN (2) CN117285547A (fr)
AR (1) AR114254A1 (fr)
AU (2) AU2019222758B2 (fr)
BR (1) BR112020015509A2 (fr)
CA (1) CA3088577A1 (fr)
CL (1) CL2020002055A1 (fr)
CR (1) CR20200403A (fr)
DK (1) DK3752510T3 (fr)
DO (1) DOP2023000016A (fr)
EA (1) EA202091930A1 (fr)
EC (1) ECSP20053845A (fr)
ES (1) ES2939775T3 (fr)
FI (1) FI3752510T3 (fr)
GE (1) GEP20237571B (fr)
HR (1) HRP20230030T1 (fr)
HU (1) HUE061046T2 (fr)
IL (2) IL294042A (fr)
JO (1) JOP20200178A1 (fr)
LT (1) LT3752510T (fr)
MA (1) MA51828B1 (fr)
MD (1) MD3752510T2 (fr)
MX (1) MX2020008268A (fr)
PE (1) PE20210454A1 (fr)
PL (1) PL3752510T3 (fr)
PT (1) PT3752510T (fr)
RS (1) RS64018B1 (fr)
SG (1) SG11202006614VA (fr)
SI (1) SI3752510T1 (fr)
TW (2) TWI828358B (fr)
UA (1) UA126304C2 (fr)
UY (1) UY38093A (fr)
WO (1) WO2019161078A1 (fr)
ZA (1) ZA202004357B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008268A (es) 2018-02-15 2020-09-21 Vertex Pharma Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
MD3880197T2 (ro) * 2018-11-14 2023-08-31 Vertex Pharma Metode de tratament pentru fibroză chistică
AU2019404934B2 (en) * 2018-12-21 2022-04-21 Novartis Ag Macrocyclic compounds and their use in the treatment of disease
TW202115092A (zh) * 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
JP2022545359A (ja) * 2019-08-14 2022-10-27 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子モジュレーター
CA3150162A1 (fr) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
CN110551077B (zh) * 2019-09-24 2023-01-31 新乡市润宇新材料科技有限公司 一种光催化分子氧氧化制备n-叔丁基-2-苯并噻唑亚磺酰胺的方法
BR112022009202A2 (pt) * 2019-11-12 2022-09-06 Genzyme Corp Heteroarilaminosulfonamidas de 6 membros para tratamento de doenças e condições mediadas por atividade deficiente de cftr
WO2021113806A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
WO2021113809A1 (fr) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides et leurs procédés d'utilisation
WO2022194399A1 (fr) * 2020-07-13 2022-09-22 Idorsia Pharmaceuticals Ltd Macrocycles en tant que modulateurs de cftr
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
EP4225765A2 (fr) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
US20230365587A1 (en) * 2020-10-07 2023-11-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230374038A1 (en) * 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225446A1 (fr) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
CN116670143A (zh) * 2020-10-07 2023-08-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
AU2021358063A1 (en) * 2020-10-07 2023-05-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (fr) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de conductance transmembranaire de la fibrose kystique
EP4247817A1 (fr) * 2020-11-18 2023-09-27 Vertex Pharmaceuticals Incorporated Macrocycles contenant un cycle 1,3,4-oxadiazole destinés à être utilisés en tant que modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Cystic fibrosis treatment methods
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharma PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
WO2023154291A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2023196429A1 (fr) * 2022-04-06 2023-10-12 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2023224924A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Formes solides de composés macrocycliques en tant que modulateurs de cftr et leur préparation
WO2023224931A1 (fr) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
WO2024054840A1 (fr) * 2022-09-07 2024-03-14 Sionna Therapeutics Composés macrocycliques, compositions et procédés d'utilisation associés
WO2024054845A1 (fr) * 2022-09-07 2024-03-14 Sionna Therapeutics Composés macrocycliques, compositions et leurs procédés d'utilisation
TW202421636A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 (3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型
WO2024056798A1 (fr) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Modulateurs du cftr macrocycliques
TW202421102A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
CN115536493A (zh) * 2022-10-20 2022-12-30 海门瑞一医药科技有限公司 一种制取3,3,3-三氟甲基-2,2-二甲基丙烷醇的简单方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2677682A (en) 1951-08-24 1954-05-04 American Cyanamid Co Sulfonamido pteridines
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN1612866A (zh) 2001-11-14 2005-05-04 特瓦制药工业有限公司 无定形和结晶形的氯沙坦钾及其制备方法
ES2328824T3 (es) 2003-11-14 2009-11-18 Vertex Pharmaceuticals Incorporated Tiazoles y oxazoles utiles como moduladores de transportadores de tipo casete de union a atp.
AU2005210474B2 (en) 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
ATE512145T1 (de) 2005-08-11 2011-06-15 Vertex Pharma Modulatoren des cystic fibrosis transmembrane conductance regulators
WO2007053641A2 (fr) 2005-11-01 2007-05-10 Mars, Incorporated Procyanidines de type a et inflammation
AU2006331565A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in CFTR assays and methods therewith
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2635760C (fr) 2005-12-28 2014-07-15 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs a cassette liant l'atp
ES2624554T3 (es) 2005-12-28 2017-07-14 Vertex Pharmaceuticals Incorporated Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida
SI2674428T1 (sl) 2006-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Modulatorji transporterjev atp-vezavne kasete
EP2021797B1 (fr) 2006-05-12 2011-11-23 Vertex Pharmaceuticals, Inc. Compositions de n-ý2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl¨-1,4-dihydro-4-oxoquinoléine-3-carboxamide
CA2668305C (fr) 2006-11-03 2017-01-03 Vertex Pharmaceuticals Incorporated Derives d'azaindole comme modulateurs de cftr
CA2689117A1 (fr) 2007-06-08 2008-12-18 Abbott Laboratories Indazoles a substitution 5-heteroaryle servant d'inhibiteurs de kinases
NZ620027A (en) 2007-09-14 2015-05-29 Vertex Pharma Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
DK2639224T3 (en) 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
NZ702159A (en) 2007-12-07 2016-03-31 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ720282A (en) * 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
AU2009282419B2 (en) 2008-08-13 2016-05-19 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
KR20110063578A (ko) 2008-09-29 2011-06-10 버텍스 파마슈티칼스 인코포레이티드 3－（6－（1－（2,2－디플루오로벤조［ｄ］［1,3］디옥솔－5－일）사이클로프로판카복스아미도）－3－메틸피리딘－2－일）벤조산의 투여 단위
CA2741718A1 (fr) * 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulateurs de regulateur de conductance transmembranaire de mucoviscidose
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
ES2532753T3 (es) 2008-11-06 2015-03-31 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
EP2408750B1 (fr) 2009-03-20 2015-08-26 Vertex Pharmaceuticals Incorporated Procédé pour préparer des modulateurs de régulateur de conductance transmembranaire de mucoviscidose
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
NZ602557A (en) 2010-03-19 2014-09-26 Vertex Pharma Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
NZ700556A (en) 2010-03-25 2016-04-29 Vertex Pharma Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
EP3150198B1 (fr) 2010-04-07 2021-09-22 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques de l'acide 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-méthylpyriodin-2-yl) d'acide benzoïque et leur administration
SI2555754T1 (sl) 2010-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Trdne farmacevtske oblike 3-(6-(1-(2,2-difluoro-benzo(d)(1,3)dioksol-5- il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline
EP3045452A1 (fr) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Procédé de production de composés cycloalkyle-carboxamide-indole
CA2796642A1 (fr) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques et leurs administrations
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
MX2013002035A (es) 2010-08-23 2013-03-25 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2, 2-difluorobenzo[d] [1, 3]dioxol-5-il)-n-(1-(2, 3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2 -metilpropano-2-il)-1h-indol-5-il) ciclopropanocarboxamida y administracion de las mismas.
EP2608775A2 (fr) 2010-08-27 2013-07-03 Vertex Pharmaceuticals Incorporated Composition pharmaceutique et ses administrations
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US9034879B2 (en) * 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
RU2640420C2 (ru) 2011-11-08 2018-01-09 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы транспортеров атф-связывающей кассеты
DK2806859T3 (da) 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
NZ629199A (en) 2012-02-27 2017-01-27 Vertex Pharma Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2838882A1 (fr) 2012-04-20 2015-02-25 Vertex Pharmaceuticals Incorporated Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
IN2014MN02574A (fr) 2012-05-22 2015-07-24 Genentech Inc
EP2858645A1 (fr) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques pour le traitement des troubles à médiation par cftr
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
CN103571906B (zh) 2012-07-27 2018-12-11 上海泽元海洋生物技术有限公司 一种利用微藻高效生产虾青素的新方法
SG11201503365YA (en) 2012-11-02 2015-06-29 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
WO2015051043A1 (fr) 2013-10-01 2015-04-09 Amgen Inc. Composés d'acylsulfonamide de biaryle en tant qu'inhibiteurs des canaux sodiques
KR102280372B1 (ko) 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
HUE062736T2 (hu) 2014-04-15 2023-12-28 Vertex Pharma Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
SI3203840T1 (sl) 2014-10-06 2020-10-30 Vertex Pharmaceuticals Incorporated Modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi
CA2963945C (fr) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-cristaux de modulateurs du regulateur de conductance transmembranaire de la mucoviscidose
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
EP4292588A3 (fr) 2015-09-21 2024-02-28 Vertex Pharmaceuticals (Europe) Limited Administration d'agents de potentialisation de cftr modifiés au deutérium
JP2019513714A (ja) 2016-03-30 2019-05-30 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
AU2017240685B2 (en) 2016-03-31 2021-08-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
BR112018070747B1 (pt) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
CN109219602A (zh) 2016-04-26 2019-01-15 艾伯维公司 囊性纤维化跨膜传导调节物蛋白的调节剂
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
AU2017280206A1 (en) 2016-06-21 2019-01-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
WO2018064632A1 (fr) 2016-09-30 2018-04-05 Vertex Pharmaceuticals Incorporated Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018081381A1 (fr) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc Composés de pyridazine, compositions et méthodes permettant de moduler cftr
US20190256474A1 (en) 2016-10-26 2019-08-22 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
EP3532469A1 (fr) 2016-10-26 2019-09-04 Proteostasis Therapeutics, Inc. Composés, compositions et méthodes permettant de moduler cftr
CA3041819A1 (fr) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Procedes de traitement avec des potentialisateurs cftr deuteres
ES2983686T3 (es) 2016-11-18 2024-10-24 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de CFTR
MX2019006637A (es) 2016-12-09 2019-08-21 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
EP3554506B1 (fr) 2016-12-16 2021-04-28 Cystic Fibrosis Foundation Dérivés d'hétéroaryle bycyclique en tant que potentialisateurs du cftr
WO2018116185A1 (fr) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Modulateurs cftr deutérés et procédés d'utilisation
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
EP3615528B1 (fr) 2017-04-28 2022-02-16 Proteostasis Therapeutics, Inc. Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US20210069174A1 (en) 2017-07-01 2021-03-11 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of cystic fibrosis
CA3069720A1 (fr) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides utilises en tant qu'inhibiteurs des canaux sodiques
EP3654969A1 (fr) 2017-07-17 2020-05-27 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
WO2019018353A1 (fr) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
EP3662079A4 (fr) 2017-07-31 2021-04-14 Technion Research & Development Foundation Limited Procédés de détection d'adn modifié et non modifié
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019071078A1 (fr) 2017-10-06 2019-04-11 Proteostasis Therapeutics, Inc. Composés, compositions et méthodes pour augmenter l'activité de cftr
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
US20210228489A1 (en) 2017-12-04 2021-07-29 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MX2020008268A (es) 2018-02-15 2020-09-21 Vertex Pharma Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
US20210009560A1 (en) 2018-03-30 2021-01-14 Vertex Pharmaceuticals Incorporated Crystalline forms of modulators of cftr
WO2019200246A1 (fr) 2018-04-13 2019-10-17 Alexander Russell Abela Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
MD3880197T2 (ro) 2018-11-14 2023-08-31 Vertex Pharma Metode de tratament pentru fibroză chistică
AU2019404934B2 (en) 2018-12-21 2022-04-21 Novartis Ag Macrocyclic compounds and their use in the treatment of disease
EP3921313A1 (fr) 2019-02-06 2021-12-15 Novartis AG Dérivés de n-(pyridin-2-yl)pyridine-sulfonamide et leur utilisation dans le traitement d'une maladie
US20220160705A1 (en) 2019-03-20 2022-05-26 Cornell University Methods for controlling prostaglandin-mediated biological processes
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (fr) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Formes solides de modulateurs de cftr
WO2020242935A1 (fr) 2019-05-29 2020-12-03 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la mucoviscidose
CA3150162A1 (fr) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
JP2022545359A (ja) 2019-08-14 2022-10-27 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子モジュレーター
BR112022009202A2 (pt) 2019-11-12 2022-09-06 Genzyme Corp Heteroarilaminosulfonamidas de 6 membros para tratamento de doenças e condições mediadas por atividade deficiente de cftr
PE20221461A1 (es) 2019-11-12 2022-09-21 Genzyme Corp Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators

Also Published As

Publication number Publication date
EP4198037A1 (fr) 2023-06-21
EP3752510B1 (fr) 2022-12-07
ZA202004357B (en) 2023-12-20
MA51828A (fr) 2020-12-23
US11866450B2 (en) 2024-01-09
IL294042A (en) 2022-08-01
EP3752510A1 (fr) 2020-12-23
MX2020008268A (es) 2020-09-21
US11066417B2 (en) 2021-07-20
TWI828358B (zh) 2024-01-01
KR102482271B1 (ko) 2022-12-27
CN112004817A (zh) 2020-11-27
PT3752510T (pt) 2023-03-15
SI3752510T1 (sl) 2023-03-31
HUE061046T2 (hu) 2023-05-28
BR112020015509A2 (pt) 2021-01-26
JP2024050811A (ja) 2024-04-10
CN117285547A (zh) 2023-12-26
PE20210454A1 (es) 2021-03-08
AU2022231721A1 (en) 2022-10-06
JP7214743B2 (ja) 2023-01-30
ECSP20053845A (es) 2020-12-31
US20190248809A1 (en) 2019-08-15
GEP20237571B (en) 2023-11-27
JP2022126802A (ja) 2022-08-30
RS64018B1 (sr) 2023-03-31
ES2939775T3 (es) 2023-04-26
AU2019222758A1 (en) 2020-08-13
CR20200403A (es) 2020-10-26
CA3088577A1 (fr) 2019-08-22
AU2019222758B2 (en) 2022-07-07
HRP20230030T1 (hr) 2023-03-03
JP2021513967A (ja) 2021-06-03
CL2020002055A1 (es) 2021-03-19
FI3752510T3 (fi) 2023-03-14
MD3752510T2 (ro) 2023-06-30
TWI780304B (zh) 2022-10-11
IL276662B (en) 2022-08-01
TW201938566A (zh) 2019-10-01
KR20200131240A (ko) 2020-11-23
UA126304C2 (uk) 2022-09-14
DOP2023000016A (es) 2023-02-28
EA202091930A1 (ru) 2021-03-12
AU2022231721B2 (en) 2024-09-19
JOP20200178A1 (ar) 2022-10-30
PL3752510T3 (pl) 2023-05-08
IL276662A (en) 2020-09-30
US20220106331A1 (en) 2022-04-07
WO2019161078A1 (fr) 2019-08-22
AR114254A1 (es) 2020-08-12
LT3752510T (lt) 2023-04-11
DK3752510T3 (da) 2023-01-16
MA51828B1 (fr) 2022-11-30
CN112004817B (zh) 2023-06-23
UY38093A (es) 2019-10-01
TW202304937A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
IL276662A (en) Macrocycles as modulators of the cystic fibrosis transmembrane conductance regulator, their pharmaceutical compounds, their use in the treatment of cystic fibrosis, and a process for their preparation.
IL277491A (en) Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
ZA201902124B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IL266286A (en) Pharmaceutical preparations for the treatment of diseases related to cystic fibrosis transmembrane conductance regulator modulators
IL273163A (en) Cystic fibrosis transmembrane conductance control protein modulators and methods of use